ABBV-RGX-314 Dose 2 clinical trials

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

This study is testing a new, one-time gene therapy called ABBV-RGX-314 for wet age-related macular degeneration (wet AMD). It aims to see if this treatment can improve vision and reduce the need for frequent eye injections, compared to the standard treatment, aflibercept (EYLEA®).